Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

11.05 -0.33 (-2.90%)
Streaming Delayed Price Updated: 1:17 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics to Participate in Upcoming Investor Conferences
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Participate in Upcoming Investor Conferences
From Rapport Therapeutics, Inc.
Via GlobeNewswire
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data 
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
Preclinical data on TARPγ8 targeted compound, an analog to Rapport’s lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models 
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.